PMID-24355990 – Melanoma Associated with Melanotan-II Use
Hjuler KF et al. "Melanoma Associated with the Use of Melanotan-II," Dermatology, 2014;228(1):34-36.
Quick Reference
| Property | Value |
|---|---|
| PMID | 24355990 |
| DOI | — |
| Year | 2014 |
| Journal | Dermatology |
| Study Type | Case Report |
| Evidence Level | IV |
| Sample | n=1 (20-year-old woman) |
| Peptide(s) Studied | Melanotan II |
Key Findings
- A 20-year-old woman developed invasive melanoma after using Melanotan-II for self-tanning
- Patient had concurrent tanning bed use, a known independent melanoma risk factor
- Pre-existing nevi showed changes (darkening, asymmetry) during MT-II use
- Melanoma arose in a pre-existing dysplastic nevus
- Causality cannot be established from a single case — confounding from UV exposure is significant
- Authors hypothesize MC1R activation by MT-II could promote melanocyte proliferation in susceptible individuals
Study Design
Single case report documenting the clinical presentation, histopathology, and temporal relationship between Melanotan-II use and melanoma diagnosis. Includes dermoscopic images and histological assessment.
Limitations
- Single case report; cannot establish causation
- Concurrent tanning bed use is a major confounder and independent melanoma risk factor
- Patient's baseline melanoma risk (skin type, nevus count, family history) not fully characterized
- MT-II dosing, duration, and source (unregulated product) not standardized
- No population-level denominator to estimate relative risk
Clinical Relevance
This case contributes to the safety signal around Melanotan-II and melanoma risk. While causality is not established, the report highlights that MT-II use combined with UV exposure may increase melanoma risk, particularly in patients with dysplastic nevi. Practitioners should counsel patients that MT-II does NOT replace sun protection, and concurrent tanning bed use should be strongly discouraged. Baseline dermatologic assessment and regular skin checks are recommended for any patient using melanotropic peptides.
Related
#research #case-report #evidence-level-IV #cancer